WFM
BMRN icon

Wilmington Funds Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wilmington Funds Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$299K Buy
4,800
+1,800
+60% +$109K 0.03% 528
2014
Q1 		$205K Hold
3,000
– – 0.02% 677
2013
Q4 		$211K Hold
3,000
– – 0.02% 690
2013
Q3 		$217K Buy
+3,000
New +$199K 0.02% 662

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wilmington Funds Management's BMRN Position: Q2 2014 in Review

Wilmington Funds Management increased its BioMarin Pharmaceuticals (BMRN) stake by 60% in Q2 2014, buying an estimated $109K and bringing the position to 4,800 shares worth $299K. The position accounts for 0.03% of the portfolio, ranked #528.

Wilmington Funds Management first reported a position in BMRN in Q3 2013 and has held it in 4 quarters since. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

  • Wilmington Funds Management held 4,800 shares of BioMarin Pharmaceuticals worth $299K as of Q2 2014.
  • Wilmington Funds Management bought 1,800 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $109K.
  • BioMarin Pharmaceuticals made up 0.03% of Wilmington Funds Management's portfolio in Q2 2014, its #528 holding.
  • Wilmington Funds Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 4 quarters since.
  • 321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.